10-Q: Annexon Reports Increased Losses Amid Clinical Progress

Annexon, Inc. reported a significant increase in net loss and R&D expenses for Q3 2025, while advancing its lead clinical programs and extending its cash runway into late Q1 2027.

Summary

• Net loss for the three months ended September 30, 2025, increased to $54.9 million, up 58% from $34.8 million in the same period of 2024.
• For the nine months ended September 30, 2025, net loss rose to $158.4 million, a 77% increase from $89.6 million in the prior year period.
• Research and development (R&D) expenses surged by 65% to $49.7 million for the three months ended September 30, 2025, and by 87% to $142.0 million for the nine months ended September 30, 2025, primarily due to increased clinical trial and manufacturing costs.
• General and administrative (G&A) expenses decreased by 22% to $7.3 million for the three months ended September 30, 2025, and by 5% to $24.1 million for the nine months ended September 30, 2025, reflecting corporate efficiencies.
• Cash and cash equivalents and short-term investments totaled $188.7 million as of September 30, 2025, down from $312.0 million as of December 31, 2024.
• The company projects its existing capital resources will fund operating expenses and capital expenditure requirements into late first quarter 2027.
• Enrollment for the global Phase 3 ARCHER II trial for vonaprument in Geographic Atrophy (GA) was completed in July 2025, with topline data expected in the second half of 2026.
• The Marketing Authorization Application (MAA) submission for tanruprubart in Guillain-Barré Syndrome (GBS) in Europe is expected in January 2026, with ongoing dialogue with the FDA for the BLA submission in the U.S.
• The company sold 5,235,959 shares of common stock under its 2024 At-the-Market (ATM) program for net proceeds of approximately $13.5 million during the nine months ended September 30, 2025, with $81.2 million remaining available.
• Subsequent to September 30, 2025, an additional 4,504,865 shares were sold under the 2024 ATM program for net proceeds of approximately $13.9 million.
• Common warrants exercisable for 6,877,622 shares were amended in June 2025, extending their term to June 30, 2026, and removing the cashless exercise option, potentially yielding $39.9 million if exercised for cash.

Sentiment

Score: 4

Explanation: The company shows strong clinical progress with lead candidates and positive regulatory interactions, which are crucial for a biopharmaceutical company. However, the significant increase in net losses and R&D expenses, coupled with a substantial decrease in cash and investments and a relatively short cash runway, indicate considerable financial challenges and a high burn rate. The need for substantial additional financing in the near future introduces significant uncertainty and potential for dilution, outweighing the clinical positives in the short term from a financial health perspective.

Positives

• Strong clinical progress for tanruprubart in GBS, with approximately 90% of patients improving by week 1 and more than twice as many achieving normal health at week 26 in the placebo-controlled Phase 3 trial.
• Tanruprubart has received Fast Track and Orphan Drug designation from the FDA and Orphan designation from the EMA for GBS.
• Completed enrollment of 659 patients in the global Phase 3 ARCHER II trial for vonaprument in GA, a significant milestone towards potential approval.
• Vonaprument has received Priority Medicine (PRIME) designation by the EMA and was selected for the Product Development Coordinator (PDC) Pilot, indicating strong regulatory support.
• ANX1502, an oral small molecule for autoimmune indications, was generally well tolerated in Phase 1 trials and showed supportive impact on a PD biomarker, with a POC study in CAD patients ongoing.
• General and administrative expenses decreased, reflecting corporate efficiencies and disciplined resource prioritization.

Negatives

• Net loss significantly increased by 58% for the three months and 77% for the nine months ended September 30, 2025, compared to the same periods in 2024.
• Research and development expenses increased substantially by 65% for the three months and 87% for the nine months ended September 30, 2025, indicating a higher cash burn rate.
• Cash and cash equivalents and short-term investments decreased from $312.0 million at December 31, 2024, to $188.7 million at September 30, 2025.
• The company has an accumulated deficit of $869.1 million as of September 30, 2025, and expects to continue incurring losses for the foreseeable future.
• Interest and other income, net, decreased by 55% for the three months and 36% for the nine months ended September 30, 2025, primarily due to lower average cash and investment balances.
• The cash runway is estimated to fund operations only into late first quarter 2027, necessitating substantial additional financing soon.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, making future viability difficult to assess.
• Substantial additional financing will be required to achieve goals, and failure to obtain it on acceptable terms could force delays, reductions, or termination of product development programs or commercialization efforts.
• The business is heavily dependent on the successful development, regulatory approval, and commercialization of product candidates, some of which are in early stages of clinical development.
• Research and development of biopharmaceutical products is inherently risky, with no assurance that any product candidates will receive regulatory approval.
• The company may encounter substantial delays in clinical trials or may not be able to conduct or complete them on expected timelines.
• The U.S. FDA and comparable foreign regulatory authorities may not accept data from clinical trials conducted outside the United States, particularly for tanruprubart's GBS data package.
• Adverse events or undesirable side effects caused by, or other unexpected properties of, any product candidates could halt clinical development, delay or prevent regulatory approval, or limit commercial potential.
• Reliance on third-party suppliers for manufacturing product candidates poses risks of loss, failure to comply with regulations, or inability to provide sufficient quantities at acceptable quality or prices.
• Successful commercialization depends on adequate coverage, reimbursement levels, and pricing policies from governmental authorities and health insurers, which may be difficult to obtain.
• Any future collaboration arrangements may not be successful, adversely affecting the ability to develop and commercialize product candidates.
• Inability to obtain, maintain, and enforce intellectual property protection could allow competitors to make, use, or sell similar products.
• The company's stock price has been and could remain volatile, potentially preventing stockholders from reselling shares at or above their purchase price.
• Actual or perceived failure to comply with data protection laws could lead to government enforcement actions, penalties, private litigation, or adverse publicity.
• Prioritization of certain product candidates or indications due to limited resources may lead to expending resources on unsuccessful products or missing more profitable opportunities.
• Conducting a global Phase 3 program for vonaprument is expensive and time-consuming, and regulatory authorities may not accept the data as sufficient for approval.
• Results of operations may fluctuate significantly, making future results difficult to predict and potentially causing them to fall below expectations.
• Public health crises could materially and adversely affect preclinical and clinical trials, business, financial condition, and results of operations.
• Even if product candidates obtain regulatory approval, they may fail to achieve broad physician and patient adoption and use necessary for commercial success.
• Orphan Drug designation benefits, including market exclusivity, may not be maintained or may be reduced.
• Breakthrough Therapy, Fast Track, or PRIME designations do not guarantee faster development, review, or approval.
• Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder timely development, approval, or commercialization.
• Product candidates approved as biologic products may face competition sooner than anticipated due to biosimilar pathways.
• Business operations and relationships with healthcare professionals are subject to healthcare regulatory laws, which could expose the company to penalties.
• The business involves hazardous materials, requiring compliance with environmental laws that can be expensive and restrictive.
• Cybersecurity risks and failure to maintain security of information technology systems or data could lead to adverse consequences.
• Use of generative artificial intelligence (AI) and/or automated decision-making technologies is subject to evolving privacy laws and could result in compliance costs or competitive disadvantages.
• The company may be subject to securities litigation, which is expensive and could divert management's attention.
• Principal stockholders and management own a significant percentage of stock, allowing them to exert significant control over matters subject to stockholder approval.
• Future sales of common stock, including from warrant exercises, could cause immediate dilution to stockholders.
• The ability to use net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes.
• Provisions in charter documents and Delaware law could discourage a takeover and lead to entrenchment of management.
• Claims for indemnification by directors and officers may reduce available funds.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• The company does not currently intend to pay dividends, so return on investment depends on stock price appreciation.

Future Outlook

The company expects to continue incurring losses and negative cash flows from operations for at least the next several years. Existing cash and cash equivalents and short-term investments are projected to fund operating expenses and capital expenditure requirements into late first quarter 2027. The company will require substantial additional financing to achieve its goals and may need to seek additional funds sooner than planned due to changes in development plans or regulatory requirements. Key milestones include the MAA submission for tanruprubart in Europe in January 2026, initial PK/PD/biomarker/functional data from the FORWARD study in 2026, and topline data from the ARCHER II trial for vonaprument in the second half of 2026. An update on the ANX1502 POC study is also expected in 2026.

Management Comments

• Management projects that existing cash and cash equivalents and short-term investments will enable the company to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements.
• Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.
• We continue to engage with applicable EU and U.S. regulators to advance tanruprubart towards registration worldwide.
• Productive regulatory interactions with European Rapporteurs and the Pediatric Committee of the European Medicines Agency reaffirmed the current data package is on track for our Marketing Authorization Application, or MAA, submission expected in January 2026.
• Dialogue with FDA is ongoing regarding the generalizability package supporting the BLA submission.
• We have established a global registration path with the FDA and EMA which supports the potential of vonaprument to be the first treatment approved in both Europe and the U.S. for the protection of vision in patients who have dry AMD with GA, assuming positive Phase 3 results.

Industry Context

Annexon operates in the highly competitive biopharmaceutical industry, specializing in neuroinflammation and complement-mediated diseases. Its focus on C1q inhibition represents a novel therapeutic approach within the complement pathway, which has been validated as a therapeutic target. The company is addressing significant unmet medical needs in rare and prevalent conditions like GBS and GA, where existing therapies are limited or non-existent. The industry faces increasing regulatory scrutiny, cost-containment pressures, and rapid technological advancements, requiring substantial R&D investment and efficient capital management. The company's global clinical trial strategy and engagement with multiple regulatory bodies (FDA, EMA) reflect the international nature of drug development and commercialization.

Comparison to Industry Standards

• For Guillain-Barré Syndrome (GBS), tanruprubart is being developed in an area with no FDA-approved therapies and no substantial evidence of effectiveness from current standard of care, positioning it to potentially fill a critical gap.
• For Geographic Atrophy (GA), vonaprument is the only investigational therapy to show significant vision preservation on assessments of best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA), and significant preservation of central retinal photoreceptors. This differentiates it from the two FDA-approved therapies for GA, which may not offer the same vision preservation benefits.
• Vonaprument's PRIME designation by the EMA and selection for the PDC Pilot indicates a higher level of regulatory recognition and support compared to many other investigational therapies in the GA space.
• The company's approach of targeting C1q, the initiating molecule of the classical complement pathway, is a novel mechanism compared to other complement inhibitors, which could offer a more complete protection against complement-mediated disorders.

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings at this time. From time to time, the company may become involved in various legal proceedings that arise in the ordinary course of business.

Related Party Transactions

• An entity related to one of the company's directors participated in the December 2023 public offering, purchasing 350,000 shares of common stock for approximately $1.0 million.
• The modification of common warrants in June 2025 included a related party transaction involving 613,497 common warrants held by a member of the board of directors, which accounted for $0.2 million of the $1.9 million deemed dividend recognized.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises (ATM program, potential warrant exercises, future equity offerings) due to increasing losses and funding needs. The stock price is highly volatile and subject to market fluctuations and clinical trial outcomes.
• **Employees**: The company plans to hire additional personnel to support growth, but also emphasizes corporate efficiencies, which could imply careful management of personnel expenses. Stock-based compensation remains a significant component of overall compensation.
• **Customers (future)**: Potential for novel therapies in GBS and GA could offer significant benefits to patients with unmet medical needs, assuming successful development and commercialization.
• **Creditors**: The company has no significant debt, but its ongoing losses and need for substantial future financing could impact its creditworthiness if debt financing is pursued.
• **Regulatory Authorities**: Ongoing engagement with FDA and EMA, including PRIME and Fast Track designations, indicates active collaboration and potential for expedited review, but also highlights the complexities and uncertainties of global regulatory pathways.

Next Steps

• Submit Marketing Authorization Application (MAA) for tanruprubart in GBS in Europe (expected January 2026).
• Continue dialogue with the FDA regarding the generalizability package for tanruprubart's BLA submission in the U.S.
• Anticipate initial pharmacokinetics (PK) and pharmacodynamics (PD) biomarker and functional data from the FORWARD study for tanruprubart in 2026.
• Report topline data from the Phase 3 ARCHER II trial for vonaprument in GA in the second half of 2026.
• Provide an update on the ANX1502 proof-of-concept (POC) study upon its completion in 2026.
• Seek substantial additional financing through equity offerings, debt financings, credit facilities, or collaborations.
• Continue to advance product candidates through late-stage clinical trials and invest in capabilities for commercialization, including manufacturing.
• Hire additional personnel to support organizational growth and commercialization activities.

Key Dates

Recommendation

Annexon, Inc. is a clinical-stage biopharmaceutical company with promising late-stage clinical assets (tanruprubart for GBS and vonaprument for GA) that have shown positive clinical data and received favorable regulatory designations. The completion of ARCHER II enrollment and upcoming MAA submission are significant milestones. However, the company's financial position has deteriorated, with a substantial increase in net losses and R&D expenses, leading to a reduced cash balance and a relatively short cash runway into late Q1 2027. This necessitates significant future capital raises, which will likely result in further shareholder dilution. While the clinical pipeline offers long-term potential, the immediate financial challenges and the inherent risks of biopharmaceutical development warrant a 'hold' recommendation. Investors should monitor upcoming clinical data readouts and the company's ability to secure additional financing on favorable terms.

Keywords

Biopharmaceutical, Neuroinflammation, Complement Pathway, Guillain-Barré Syndrome, GBS, Geographic Atrophy, GA, Dry AMD, Autoimmune Diseases, Clinical Trials, Phase 3, Regulatory Approval, FDA, EMA, Orphan Drug, Fast Track, PRIME Designation, Tanruprubart, Vonaprument, ANX1502, Cash Runway, Capital Raise, ATM Program, R&D Expenses, Net Loss, Biotech, Drug Development